Ona et al. 2022: Adverse Events of Ibogaine in Humans (2015–2020 Systematic Review)

Definition box

Definition: Ona et al. (2022) in *Psychopharmacology* (doi: 10.1007/s00213-021-05964-y; PMID 34406452; e-pub 2021) is a PRISMA systematic review updating human adverse events and fatalities associated with ibogaine/noribogaine for 2015–2020. Authors included 18 studies, found highly heterogeneous products and dosages, and classified AEs into acute (<24 h) effects—mainly cardiac (most commonly QTc prolongation), gastrointestinal, neurological, and clinical alterations—and longer-lasting (>24 h) effects including persistent cardiac, psychiatric, and neurological signs. They call for Phase I trials with standardized products, vulnerable-population profiling, and better screening/clinical procedures. This AE map is not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). Causation is often hard to prove from case reports. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (55 words)

Ona and colleagues’ 2022 Psychopharmacology systematic review of eighteen 2015–2020 studies mapped acute ibogaine adverse events—especially QTc prolongation—plus longer-lasting cardiac, psychiatric, and neurological problems. Heterogeneous products limit certainty. It does not prove psychoactive IV ibogaine infusion. Screening and medical monitoring remain essential. Not FDA-approved.

Why this paper-spoke exists

Efficacy blogs cherry-pick withdrawal anecdotes; AE reviews are the counterweight. Ona is a citation magnet for QTc and fatality discussions and should sit next to setting-factor and CV teaching pages. Related: /blog/ibogaine-mortality-cardiac-risk, /blog/ibogaine-setting-factors-safety-review-2023, /safety-and-screening.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Ona G., Rocha J.M., Bouso J.C., Hallak J.E.C., Borràs T., Colomina M.T., dos Santos R.G. *Psychopharmacology (Berl)*. 2022;239(6):1977–1987. doi 10.1007/s00213-021-05964-y | | Type | PRISMA systematic review (AE/fatality update) | | Window | Literature ~2015–2020 (search described by authors) | | Included | 18 studies in final selection | | Scope | Ibogaine and noribogaine human adverse events | | Key limitation noted | Case reports / non-controlled settings → causation often unclear |

Methods (plain language)

Reviewers systematically searched for human reports of ibogaine/noribogaine adverse events in the update window, screened for eligibility, and tabulated acute versus longer-lasting harms. Special attention in related ICEERS summaries includes concomitant drug use as a complicating factor. Systematic AE reviews catalog signals; they do not invent a single universal incidence rate when products and doses differ wildly.

Key findings (no hype)

Author-facing themes:

• Product type and known dosages were highly heterogeneous.
• Acute (<24 h) AEs: mainly cardiac (QTc prolongation most common), plus GI, neurological, and other clinical alterations.
• Longer-lasting (>24 h) AEs: persistent cardiac alterations, psychiatric signs, neurological signs.
• Fatalities and serious AEs appear in the literature; many reports are uncontrolled, so causation is not always clear.
• Authors conclude there is a high need for Phase I trials describing safety of different dosages with standardized products, plus clinical profiling of vulnerable populations and better screening/procedures.

Honest reading: “causation hard to prove” is not the same as “safe until proven otherwise.”

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Case-report dominance | Selection and reporting bias | | Unknown/variable products | Root bark ≠ pharma HCl ≠ mystery capsules | | Polypharmacy / concurrent drugs | Confounds attribution | | Incomplete dosing data | Hard to build exposure–response from sparse cases | | Search window ends ~2020 | Later papers need separate spokes | | Review ≠ new ECG study | Still must read Knuijver primary data |

Route honesty: oral ≠ psychoactive IV

Ona aggregates harms from mostly oral/clinic/unspecified human exposures. It does not create a psychoactive-IV safety dossier. Brand IV ibogaine infusion still requires physician supervision, ECG, electrolytes, and continuous monitoring culture. Support IV ≠ psychoactive IV (/blog/ibogaine-oral-vs-iv).

Cardiac / YMYL context

Ona’s “most common acute cardiac AE = QTc prolongation” aligns with:

• Knuijver 2021 magnitudes (/blog/knuijver-2021-ibogaine-qtc-safety)
• Knuijver 2024 concentration–response (/blog/knuijver-2024-ibogaine-pk-cyp2d6)
• Brunt *Addiction* VT/QTc teaching (/blog/ibogaine-cardiovascular-complications-review)
• Setting-factor requirements (/blog/ibogaine-setting-factors-safety-review-2023)

Families comparing clinics should treat missing telemetry as a walk-away criterion (/blog/ibogaine-telemetry-acls-monitoring, /blog/cheap-ibogaine-clinic-red-flags).

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “AE review means it never helps anyone” | Overclaim—review is harm-focused, not efficacy RCT | | “Case reports = ignore cardiac risk” | False | | “Standardized product alone erases QTc” | False — still need monitoring | | Cite as harm inventory with screening implications? | Yes |

U.S. Schedule I / not FDA (/blog/is-ibogaine-legal-us).

Practical checklist derived from AE-review themes

1. Pre-dose ECG + electrolytes + med reconciliation (CYP2D6 inhibitors).
2. Known identity/purity of ibogaine product.
3. Continuous cardiac monitoring plan ≥ risk window.
4. Psychiatric observation capacity for delayed neuro/psych AEs.
5. Written emergency transfer pathway.
6. No cure guarantees in consent forms (/blog/ibogaine-informed-consent-questions).

Soft CTA

If Ona’s AE taxonomy made clinic marketing look thin, that is appropriate. For physician-supervised IV ibogaine infusion questions, start at /safety-and-screening, then /apply. Mortality synthesis: /blog/ibogaine-mortality-cardiac-risk.

FAQ

What is Ona 2022? A PRISMA systematic review of human ibogaine/noribogaine adverse events and fatalities covering roughly 2015–2020 (18 studies).

What was the most common acute cardiac AE theme? QTc prolongation (as emphasized by the authors).

Are all AEs proven causal? No—authors note causation is often unclear in case reports/non-controlled settings.

Does this prove IV ibogaine infusion is unsafe or safe? It maps harms in mostly non-IV literature; it is not an IV RCT. Cardiac caution still applies.

Why call for Phase I trials? To describe safety of different dosages with standardized products under controlled conditions.

Should families still screen? Yes—non-negotiable (/safety-and-screening).

Is product heterogeneity a real problem? Yes—authors highlight highly heterogeneous products and dosages.

Is ibogaine FDA-approved? No. Schedule I in the U.S.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Ona 2022 is human AE literature synthesis—not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Ona G., Rocha J.M., Bouso J.C., Hallak J.E.C., Borràs T., Colomina M.T., dos Santos R.G. The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020). *Psychopharmacology (Berl)*. 2022;239(6):1977–1987. doi: 10.1007/s00213-021-05964-y. PMID: 34406452.
2. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
3. Rocha J.M. et al. Setting factors… *Eur Arch Psychiatry Clin Neurosci*. 2023. doi: 10.1007/s00406-023-01590-1.
4. Brunt T.M. *Addiction*. 2026. doi: 10.1111/add.70319.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).